Business Strategy

Immuron’s current strategy is to develop its product candidates to the stage that they can be out-licensed in a manner designed to deliver greatest shareholder value. Such licensing arrangements are intended to provide Immuron with upfront, milestone-based and royalty bearing payments.  A key feature of this strategy is that any such license will be coupled with a supply arrangement under which Immuron maintains and controls the supply and production of its hyper-immune dairy derived products, thereby maintaining control over its technology platform. The timing and the nature of the licenses are expected to vary according to the profile and stage of development for each product.